Select Publications

Conference Papers

Srinivasan A; De Cruz P; Sam M; Toong C; Van Langenberg D, 2022, 'Upfront infliximab dose intensification for secondary loss of response in IBD: similar efficacy to dose interval shortening with the added advantage of early clinical and pharmacokinetic predictors of response', in JOURNAL OF CROHNS & COLITIS, OXFORD UNIV PRESS, pp. I437 - I438, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000778573401167&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Srinivasan A; De Cruz P; Sam M; Toong C; van Langenberg D, 2022, 'Upfront infliximab dose intensification for secondary loss of response in IBD: similar efficacy to dose interval shortening with the added advantage of early clinical and pharmacokinetic predictors of response', in JOURNAL OF CROHNS & COLITIS, OXFORD UNIV PRESS, pp. I437 - I438, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000778573400589&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Lin B; Wu Y; Thilakanathan C; Lehmann P; Xuan W; Mohsen W; Toong C; Ng W; Connor S, 2017, 'Biological level testing in inflammatory bowel disease identifies inappropriate use of infliximab, with substantial associated cost savings', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY, pp. 132 - 133, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000407897100240&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Wu Y; Lin B; Thilakanathan C; Lehmann P; Xuan W; Mohsen W; Toong C; Ng W; Connor S, 2017, 'Secondary loss of response is the most common indication for infliximab level testing in inflammatory bowel disease: The Australian experience', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY, pp. 153 - 154, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000407897100273&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Mitrev N; Vande Casteele N; Seow C; Andrews JM; Connor SJ; Moore G; Barclay M; Begun J; Bryant R; Chan W; Corte C; Ghaly S; Lemberg DA; Kariyawasam V; Lewindon P; Martin J; Mountifield R; Radford-Smith G; Slobodian P; Sparrow M; Toong C; Van Langenberg D; Ward MG; Leong RW, 2017, 'Therapeutic drug monitoring-guided biological drug therapy in inflammatory bowel disease: Consensus statements of the Australian Inflammatory Bowel Disease Association (AIBDA) and Gastroenterological Society of Australia (GESA)', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY, pp. 136 - 138, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000407897100247&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Barker R; Toong C, 2013, 'AN AETIOLOGY FOR IgG4 RELATED DISEASE?', in INTERNAL MEDICINE JOURNAL, WILEY-BLACKWELL, pp. 22 - 22, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000323685200066&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1


Back to profile page